PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its board of directors, strengthening governance and strategic oversight as the biotechnology company advances its induced pluripotent stem cell platform toward clinical milestones.
The company said Lee will serve on the audit and compensation committees, while Murphy will join the compensation and the nominating and corporate governance committees. The additions expand the board’s financial, investment, and corporate development expertise at a time when Century is prioritizing execution and capital discipline.
Chief Executive Officer Brent Pfeiffenberger said the appointments come as Century pushes its most differentiated programs closer to patients, including CNTY-813, an investigational off-the-shelf cell therapy being developed for type 1 diabetes. He said the board will benefit from Lee’s experience in capital formation and corporate development, along with Murphy’s background in life sciences investing and company creation across public and private markets.
Lee most recently served as president and chief financial officer of ImmPACT Bio, a clinical-stage biotechnology company acquired by Lyell Immunopharma in 2024. Earlier, he held chief financial officer roles at Neogene Therapeutics and Arcellx and worked in corporate development and ventures at AstraZeneca. He holds a doctorate in genetics and an MBA from Yale University, along with a bachelor’s degree in molecular cell biology from the University of California, Berkeley.
Murphy brings extensive boardroom and investment experience. He currently serves as chair or director at several life sciences organizations, including Synairgen and Cora Biosciences, and holds a leadership role with Legal & General UK Universities Ventures. He previously co-founded Syncona and led Syncona Investment Management, following earlier roles at MVM Life Science Partners, 3i Group, and McKinsey & Company. Murphy earned a doctorate from the University of Cambridge and a master’s degree in biochemistry from the University of Oxford.
Century Therapeutics is developing iPSC-derived cell therapies aimed at delivering scalable, potentially curative treatments for high-impact diseases. The board appointments signal a focus on governance depth and strategic rigor as the company prepares to transition key programs into the clinic and navigate the financial and operational demands that accompany that shift.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.